ライフサイエンスコーパス: fatal

1 ngly not clinically important to potentially fatal.

2 severe necrotizing pneumonia, which is often fatal.

3 rointestinal emergency, which is potentially fatal.

4 It can result in paralysis and may be fatal.

5 is a debilitating X-linked disorder that is fatal.

6 ); 2 cases were self-limiting and 1 case was fatal.

7 h increasing incidence worldwide that can be fatal.

8 drome; five events after follow-up HSCT were fatal.

9 ed-shockable OHCA is poor but not invariably fatal.

10 ry fibrosis (IPF) is progressive and rapidly fatal.

11 .57; p<0.0001), particularly if disabling or fatal (10.26, 4.37-24.13; p<0.0001).

12 e control group; RR 1.22, 0.88-1.68]) or non-fatal (1135 vs 1153; RR 0.97, 0.86-1.08) self-harm event

13 treated percutaneously, 12 surgically, and 3 fatal); 3 procedure-related strokes (0.078%); 9 device e

14 rointestinal bleeds were mostly disabling or fatal (45 [62%] of 73 patients vs 101 [47%] of 213 patie

15 h no significant difference in the number of fatal (82 in the intervention group vs 67 in the control

16 , although AB60 had no effect on the rate of fatal accidents, it did decrease the rate of hit and run

17 the treatment groups (one [2%] patient with fatal acute lymphocytic leukaemia in the lenalidomide gr

18 on that can be used to predict the risk of a fatal acute myocardial infarction in such patients, whic

19 Because amyotrophic lateral sclerosis is a fatal adult-onset neurodegenerative disease produced by

20 One fatal adverse event was reported in each of the treatmen

21 There were five fatal adverse events (three [2%] patients in the lenalid

22 e placebo group, 23 (8%) of 299 patients had fatal adverse events due to disease progression, and eig

23 otumumab group, 33 (11%) of 298 patients had fatal adverse events due to disease progression, and nin

24 erent risk categories for both fatal and non-fatal adverse outcomes (NRI -0.027 [95% CI -0.039, -0.01

25 There were no reports of fatal anaphylaxis.

26 ividuals suffered at least one CVD event (36 fatal and 53 nonfatal).

27 and serious cardiovascular problem with both fatal and long-term consequences.

28 ancies to different risk categories for both fatal and non-fatal adverse outcomes (NRI -0.027 [95% CI

29 This Article describes the epidemiology of fatal and non-fatal injuries from the study.

30 INTERPRETATION: The burden of fatal and non-fatal injuries in rural Bangladesh is subs

31 Males had more fatal and non-fatal injuries than females across all ext

32 nalysed the data for descriptive measures of fatal and non-fatal injury outcomes.

33 of GLP-1 receptor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non

34 dial infarction, stroke, and heart failure), fatal and non-fatal myocardial infarction, fatal and non

35 tle is known about the relative incidence of fatal and non-fatal self-harm in young people.

36 s survey (2015) to estimate the incidence of fatal and non-fatal self-harm per 100 000 person-years i

37 n fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unsta

38 , fatal and non-fatal myocardial infarction, fatal and non-fatal strokes, cardiovascular mortality, n

39 years was associated with increased risk of fatal and nonfatal CHD during 12.5 years of follow-up.

40 We compared fatal and nonfatal CHD incidence and CHD case-fatality a

41 Fatal and nonfatal CHD incidence was assessed from basel

42 We measured MGO at baseline and recorded fatal and nonfatal CVD over a median follow-up of 12.3 y

43 nd according to race/ethnicity and intent in fatal and nonfatal firearm injuries (FFIs and NFIs) in U

44 ring which 12 (0.5%) and 122 (5.1%) suffered fatal and nonfatal incident ASCVD, respectively.

45 ity related to stroke, major cardiac events (fatal and nonfatal myocardial infarction and sudden card

46 65 patient-years), to assess CVEs, including fatal and nonfatal myocardial infarction, ischemic strok

47 n score >100 AU; (2) ASCV events, defined as fatal and nonfatal myocardial infarction, other coronary

48 We systematically reviewed data on fatal and nonfatal rheumatic heart disease for the perio

49 familial NK cell deficiency that results in fatal and severe viral disease.

50 ed myocardial infarctions (MIs; nonfatal and fatal) and acute CHD deaths.

51 two cancers need not be viewed as inevitably fatal, and can be cured, particularly if detected and tr

52 far the most geographically extensive, most fatal, and longest lasting epidemic in Ebola's history,

53 igher MGO levels were associated with total, fatal, and nonfatal incident CVD (hazard ratios [HRs] 1.

54 cells, progressive loss of bone marrow, and fatal aplastic anemia between 3 and 4 months of age.

55 e for respiratory acidosis in triggering the fatal arrhythmia underlying SUNDS.

56 A case of fatal aspergillosis due to a TR46/Y121F/T289A azole-resi

57 n the past year (+2 points), history of near-fatal asthma (+1 point), body mass index >/=25kg/m(2) (+

58 ce to medications, previous episodes of near-fatal asthma, and whether the patient has experienced mu

59 e obtained from subjects who died because of fatal asthma.

60 part from causing hearing deficit, may prove fatal at times.

61 5% CI 2.27-4.24; p<0.0001), particularly for fatal bleeds (5.53, 2.65-11.54; p<0.0001), and was susta

62 Glioblastoma is an immunosuppressive, fatal brain cancer that contains glioblastoma stem-like

63 vian influenza A (H5N1) virus are frequently fatal but the mechanisms of disease remain ill-defined.

64 Frataxin KO results in fatal cardiomyopathy, whereas skeletal muscle was asympt

65 We report a fatal case of DTV encephalitis following a documented bi

66 Meningitis was diagnosed in nearly half the fatal cases (71/150 [47%]).

67 gh incidence and yields a relevant number of fatal cases (about 20,000) every year worldwide.

68 expression properties discriminated between fatal cases and survivors, we identify a small panel of

69 We report 2 fatal cases of congenital Zika virus (ZIKV) infection.

70 Most severe and fatal cases of pertussis occur in infants <8 weeks of ag

71 Overall, 132 isolates from fatal cases were serotyped (88%) and 35 distinct serotyp

72 pathologic lung tissue and to specimens from fatal cases, poor diagnostic accuracy of assays (especia

73 portant modulator of inflammation, in dengue fatal cases.

74 odystrophy (ALD) may switch phenotype to the fatal cerebral form (ie, cerebral ALD [cALD]), the cause

75 onfidence interval, 0.41-0.73) of developing fatal CHD compared with those least socially integrated

76 s, black men and women have similar risk for fatal CHD compared with white men and women, respectivel

77 sepsis hospitalizations and future acute and fatal CHD events using Cox regression, Gray's model, and

78 Fatal CHD included deaths </=28 days of an acute MI and

79 rette smoking; however, the association with fatal CHD risk remained after accounting for these behav

80 Risk of fatal CHD was similarly higher for sepsis than nonsepsis

81 .92) and 1.09 (0.62-1.93), respectively, for fatal CHD, and 0.64 (0.47-0.86) and 0.67 (0.48-0.95), re

82 .24) and 1.00 (0.54-1.85), respectively, for fatal CHD, and 0.70 (0.51-0.97) and 0.70 (0.46-1.06), re

83 .06) and 2.11 (1.32-3.38), respectively, for fatal CHD, and 0.82 (0.64-1.05) and 0.94 (0.69-1.28), re

84 .34) and 1.79 (1.06-3.03), respectively, for fatal CHD, and 1.47 (1.13-1.91) and 1.29 (0.91-1.83), re

85 included nonfatal myocardial infarction and fatal CHD.

86 associated with lower CHD risk, particularly fatal CHD.

87 V infection can result in various, and often fatal, clinical sequelae, including fulminant infectious

88 igh-risk patients and avoid this potentially fatal complication.

89 of innate and adaptive immunity often causes fatal complications.

90 It is a common, serious, and often fatal condition among older patients.

91 itary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunc

92 Long-QT syndrome is a potentially fatal condition for which 30% of patients are without a

93 ospinal fluid (CSF), which is a frequent and fatal condition mediated by unknown mechanisms.

94 is the etiological agent of the potentially fatal condition, botulism.

95 ndividuals from four unrelated families with fatal congenital pontocerebellar hypoplasia, whereas a c

96 o cutaneous radiation syndrome, a frequently fatal consequence of exposures from nuclear accidents.

97 o determine the long-term risks of acute and fatal coronary heart disease (CHD) events after sepsis h

98 , myocardial infarction, ischemic stroke, or fatal coronary heart disease).

99 atal stroke, nonfatal myocardial infarction, fatal coronary heart disease, or heart failure.

100 763 events), 1.67 (95% CI: 1.50 to 1.86) for fatal CVD (7,775 events), 1.59 (95% CI: 1.38 to 1.83) fo

101 ident CVD (IRR, 1.39; 95% CI, 1.16-1.67) and fatal CVD (IRR, 2.33; 95% CI, 1.49-3.67) compared with t

102 of conventional risk factors, strongest for fatal CVD, and applies to both CHD and stroke.

103 For fatal CVD, associations were stronger in North American

104 Likelihood of fatal decompression increases with increasing depth of g

105 ntington's disease (HD) is a progressive and fatal degenerative disorder that results in debilitating

106 ifocal leukoencephalopathy (PML) is an often-fatal demyelinating disease of the central nervous syste

107 r infection were age younger than 12 months, fatal disease (via ultimately and rapidly fatal McCabe s

108 od cerebral adrenoleukodystrophy (cALD) is a fatal disease associated with progressive cerebral demye

109 s (HIV) infection from an almost universally fatal disease to a chronic infection for the majority of

110 of BCR-ABL1 have transformed CML from a once-fatal disease to a manageable one for the vast majority

111 anged acute myeloid leukemia (AML) remains a fatal disease with a high rate of relapse and therapeuti

112 Some transmitted aggregates can cause fatal disease, as with human iatrogenic prion diseases,

113 cies are rare yet result in severe and often fatal disease, particularly as a result of viral suscept

114 Conclusion MPM is an aggressive and rapidly fatal disease.

115 tagonists as potential therapeutics for this fatal disease.

116 results in some of the most debilitating and fatal diseases, including pancreatic cancer and diabetes

117 rus persists in vivo and causes disabling or fatal diseases.

118 c pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease trajectory.

119 y acidic protein (GFAP) lead to the rare and fatal disorder, Alexander disease (AxD).

120 PNPO deficiency leads to potentially fatal early infantile epileptic encephalopathy, severe d

121 ss of Treg number and function, leading to a fatal, early-onset autoimmune disorder.

122 ly control of virus replication, viremia and fatal Ebola virus disease (EVD).

123 g myelitis (4) , meningoencephalitis (5) and fatal encephalitis (6) .

124 iruses that are capable of causing acute and fatal encephalitis in many mammals, including humans.

125 Data for fatal estimates were based on vital registration and ver

126 One fatal event of neutropenic sepsis was reported in a pati

127 e of medulloblastoma is a nearly universally fatal event, with no significant salvage rate.

128 ue to disease progression, and nine (3%) had fatal events not due to disease progression.

129 e to disease progression, and eight (3%) had fatal events not due to disease progression.

130 The fatal events of SIDS are characterized by severe bradyca

131 n was halted in 1999 after the occurrence of fatal events related to L. loa infection.

132 D (sCJD) n = 23, familial CJD (gCJD) n = 17, fatal familial insomnia (FFI) n = 9, Gerstmann-Straussle

133 ann-Straussler-Scheinker syndrome (GSS), and fatal familial insomnia.

134 Gerstmann-Straussler-Scheinker syndrome and fatal familial insomnia.

135 fibrosis (IPF) is a chronic, progressive and fatal fibrotic lung disease characterized by profound ch

136 ence of cancer therapy and ultimately proves fatal for the majority of patients.

137 protein, triggering a debilitating and often fatal form of infantile Parkinsonism known as AADC defic

138 What distinguishes fatal from non-fatal outcomes remains largely unknown, y

139 proportion with severe, life-threatening, or fatal (grade 3-5) treatment-related adverse events by 52

140 attack host normal tissues through the often fatal graft-versus-host disease (GVHD).

141 ection of the eye and the almost universally fatal granulomatous amoebic encephalitis.

142 Epithelial ovarian cancer (EOC) is the most fatal gynaecological malignancy.

143 ies, to sustained reticulocytopenia, to near-fatal haemolysis.

144 swelling as the most prominent predictor of fatal HCM.

145 Arenaviruses cause fatal hemorrhagic disease in humans.

146 rican continent to cause epidemics of highly fatal hemorrhagic fever.

147 Mutations in ATP7B cause the potentially fatal hepatoneurological disorder Wilson disease.

148 scular atrophy is an untreatable potentially fatal hereditary disorder caused by loss-of-function mut

149 nts of human lysozyme linked with a rare but fatal hereditary systemic amyloidosis.

150 Trypanosoma brucei causes fatal human African trypanosomiasis and evades the host

151 us transmits a highly contagious, frequently fatal human disease for which there is no specific antiv

152 d virus as a critical source of exposure for fatal human infection and reveal that direct viral effec

153 Glioblastoma (GBM) remains one of the most fatal human malignancies due to its high angiogenic and

154 f low renin hypertension that is potentially fatal if untreated.

155 oNT/A) causes a debilitating and potentially fatal illness known as botulism.

156 ugh two opposing mechanisms: protection from fatal immunity by amphiregulin expression and augmentati

157 Refractory hypotensive shock was fatal in 55 of 115 patients treated with angiotensin II

158 often clinically mild, HEV can be severe or fatal in certain demographics, such as expectant mothers

159 s and septic shock are common and, at times, fatal in pediatrics.

160 eadily diagnosed and managed but potentially fatal in severe cases if untreated.

161 Of the 597 disabling/fatal incident ischaemic strokes, 369 occurred at age >/

162 An infant presented with fatal infantile lactic acidosis and cardiomyopathy, and

163 comorbidity had around 4 times the risk for fatal infection than those without (adjusted hazard rati

164 purified MERSMA clone caused weight loss and fatal infection.

165 at it may cause high morbidity and sometimes fatal infections in immunocompetent hosts and is thus an

166 Fatal infections or sepsis were significantly more commo

167 and 5 patients (4%) had life-threatening or fatal infections.

168 a Treg-specific deletion of LKB1 developed a fatal inflammatory disease characterized by excessive TH

169 describes the epidemiology of fatal and non-fatal injuries from the study.

170 INTERPRETATION: The burden of fatal and non-fatal injuries in rural Bangladesh is substantial, accou

171 Males had more fatal and non-fatal injuries than females across all external causes e

172 ges, and falls caused the most number of non-fatal injuries.

173 ta for descriptive measures of fatal and non-fatal injury outcomes.

174 Non-fatal injury rates were also highest in children aged 1-

175 Fatal injury rates were highest in children aged 1-4 yea

176 e in the phenotype determination of sporadic fatal insomnia (sFI) and a subtype of sporadic Creutzfel

177 a viable strategy for minimizing potentially fatal interactions among ALAN, structures, and birds.

178 ulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease.

179 ulmonary fibrosis (IPF) is a progressive and fatal interstitial pneumonia.

180 haemic stroke), and outnumbered disabling or fatal intracerebral haemorrhage (n=45 vs n=18), with an

181 Most fatal IPD cases are currently not vaccine-preventable.

182 osite of recurrent nonfatal ischemic stroke, fatal ischemic stroke, or early death after randomizatio

183 The PEG-CBS treatment prevented an otherwise fatal liver disease characterized by steatosis, death of

184 iensis (Nb)-infected hRETNTg(+) mice after a fatal LPS dose compared with naive mice or Nb-infected h

185 RSV LRTI accounted for 57% fatal LRTI tested for the virus.

186 ause of invasive aspergillosis, a frequently fatal lung disease primarily affecting immunocompromised

187 pathic pulmonary fibrosis (IPF) is a chronic fatal lung disease with dismal prognosis and no cure.

188 on of single HSC fate decisions is linked to fatal malignancies such as leukemia, it is important to

189 f cutaneous T-cell lymphoma (CTCL), an often-fatal malignancy of skin-homing CD4(+) T cells for which

190 e into a more aggressive, metastasizing, and fatal malignancy.

191 s, fatal disease (via ultimately and rapidly fatal McCabe scores), prolonged length of stay, and the

192 from a self-limiting meningitis to a rapidly fatal meningoencephalitis with multiorgan failure.

193 Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron degenerative disease.

194 itutive NIK expression in all T cells causes fatal multi-organ autoimmunity associated with hyperacti

195 lenalidomide group and one patient (3%) with fatal multifocal leukoencephalopathy in the placebo grou

196 otein 41 (KLHL41) cause nemaline myopathy, a fatal muscle disorder associated with sarcomere disarray

197 sive disorder characterized by severe, often fatal muscle weakness due to loss of motor neurons.

198 on Pooled Cohort Equations (for fatal or non-fatal myocardial infarction or stroke, C-statistics 0.61

199 composite outcome (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), deat

200 ot limited to, cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke.

201 imary outcome (cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke; HR 0.

202 tor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non-fatal stroke,

203 n, stroke, and heart failure), fatal and non-fatal myocardial infarction, fatal and non-fatal strokes

204 ny cause, cardiovascular death, fatal or non-fatal myocardial infarction, fatal or non-fatal stroke,

205 ny cause, cardiovascular death, fatal or non-fatal myocardial infarction, fatal or non-fatal stroke,

206 h a primary diagnosis of heart failure), non-fatal myocardial infarction, non-fatal stroke, and atria

207 point composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospital

208 use of other glucose-lowering drugs for non-fatal myocardial infarction, non-fatal stroke, or atrial

209 as death from cardiovascular causes and non-fatal myocardial infarction, stroke, and heart failure),

210 ients with metastatic melanoma who developed fatal myocarditis during ipilimumab and nivolumab combin

211 England to quantify the burden of severe or fatal necrotising enterocolitis confirmed by laparotomy,

212 quently, Cu dysregulation is associated with fatal neonatal disease, liver and cardiac dysfunction, a

213 ic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease characterized by degener

214 d to amyotrophic lateral sclerosis (ALS) - a fatal neurodegenerative disease.

215 ieved to be the cause of a group of rare and fatal neurodegenerative diseases.

216 Niemann-Pick type C (NPC) disease is a fatal neurodegenerative disorder caused by mutations in

217 rion diseases are a group of progressive and fatal neurodegenerative disorders characterized by depos

218 hies (TSEs) or prion diseases are a group of fatal neurodegenerative disorders that include Kuru, Cre

219 Prion diseases are fatal neurodegenerative disorders with sporadic, genetic

220 e ranges from mild febrile illness to severe fatal neurologic infection.

221 sible spongiform encephalopathies (TSEs) are fatal neurological disorders caused by prions, which are

222 muscular atrophy (SMA) is a common and often fatal neuromuscular disorder caused by low levels of the

223 art Association Pooled Cohort Equations (for fatal or non-fatal myocardial infarction or stroke, C-st

224 death from any cause, cardiovascular death, fatal or non-fatal myocardial infarction, fatal or non-f

225 death from any cause, cardiovascular death, fatal or non-fatal myocardial infarction, fatal or non-f

226 h, fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, hospital admission for unstab

227 h, fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, hospital admission for unstab

228 Adverse events were defined as fatal or nonfatal aortic rupture, rapid aortic growth (>

229 failure, or atrial fibrillation) and ASCVD (fatal or nonfatal myocardial infarction or stroke) were

230 Incident CHD included fatal or nonfatal myocardial infarction, acute coronary

231 e rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfat

232 es, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart fail

233 dent CVD, defined by the first occurrence of fatal or nonfatal stroke, nonfatal myocardial infarction

234 y efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the princi

235 For PRx, those patients with a fatal outcome also had a higher (more impaired) PRx thro

236 actors, notably underlying comorbidities, on fatal outcome of Middle East respiratory syndrome (MERS)

237 However, the ability of ICP to predict a fatal outcome remained relatively stable over time.

238 er Injury Network prospective study having a fatal outcome within 2 years of onset.

239 n of ICP and PRx and their relationship with fatal outcome, indicating a potential early prognostic a

240 was reversible in all but one patient with a fatal outcome.

241 tially among persons with diabetes, although fatal outcomes declined less among those with type 2 dia

242 Reston virus (RESTV) to severe disease with fatal outcomes for EBOV.

243 d impaired NO bioactivity is associated with fatal outcomes in malaria.

244 ures) and the mortality index (the number of fatal outcomes per 10,000 exposures).

245 What distinguishes fatal from non-fatal outcomes remains largely unknown, yet is key to op

246 th type 2 diabetes had smaller reductions in fatal outcomes than controls.

247 Reductions in fatal outcomes were similar in patients with type 1 diab

248 associated with increased risks of rare but fatal outcomes, including stillbirth and neonatal mortal

249 Considering the <2 % rate of anaphylaxis, fatal outcomes, modest predictive value of ST, resource

250 nts, of which six (16%) were associated with fatal outcomes.

251 y outcome was suicide attempts (nonfatal and fatal) over the 52-week follow-up period.

252 Five fatal overdoses occurred (two in the XR-NTX group and th

253 Exposure of Africans to fatal pathogens, such as Plasmodium falciparum, Lassa Vi

254 sponses to transcriptional disruptors in the fatal pediatric brain tumor, diffuse intrinsic pontine g

255 or TC, albeit with a potential high risk of fatal pneumonitis.

256 er (BBB) damage is the major risk factor for fatal post-thrombolysis ICH, but rapidly assessing BBB d

257 1 and rs16902094, 25(OH)D concentration, and fatal prostate cancer warrant replication.

258 y or from the lowest socioeconomic group and fatal respiratory disease cases aged >/=60 y were underr

259 al disease cases and 18% (95% CI 16%-21%) of fatal respiratory disease cases residing at 10 km distan

260 sease and at distances greater than 7 km for fatal respiratory disease.

261 onotic emerging paramyxovirus that can cause fatal respiratory illness or encephalitis in humans.

262 severe neurological infectious diseases and fatal respiratory infectious diseases in Bangladesh.

263 ll debris by macrophages in the heart fuel a fatal response to MI by activating IRF3 and type I IFN p

264 fatal self-harm, and community-occurring non-fatal self-harm in adolescents in England.

265 bout the relative incidence of fatal and non-fatal self-harm in young people.

266 ) to estimate the incidence of fatal and non-fatal self-harm per 100 000 person-years in adolescents

267 ncidence of suicide, hospital-presenting non-fatal self-harm, and community-occurring non-fatal self-

268 ve bacteria have increased the prevalence of fatal sepsis in modern times.

269 One fatal serious adverse event deemed unrelated to study tr

270 n n=1) and no placebo recipients experienced fatal serious adverse events suspected to be study drug-

271 ng patient survival in an almost universally fatal setting (HGG).

272 del, recurrent moderate hypoglycemia reduced fatal severe hypoglycemia-induced cardiac arrhythmias.

273 are and proceeded to HSCT, one (3%) had (non-fatal) sinusoidal obstruction syndrome that was ongoing

274 al host antimicrobial strategies, leading to fatal staphylococcal infection.

275 th, non-fatal myocardial infarction, and non-fatal stroke), death from any cause, cardiovascular deat

276 ilure), non-fatal myocardial infarction, non-fatal stroke, and atrial fibrillation.

277 differences in hemorrhagic stroke, disabling/fatal stroke, cardiovascular/unexplained death, all-caus

278 death, non-fatal myocardial infarction, non-fatal stroke, hospital admission for unstable angina, an

279 on-fatal myocardial infarction, fatal or non-fatal stroke, hospital admission for unstable angina, ho

280 on-fatal myocardial infarction, fatal or non-fatal stroke, hospital admission for unstable angina, ho

281 n-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unstable angina, or

282 ugs for non-fatal myocardial infarction, non-fatal stroke, or atrial fibrillation.

283 ty, non-fatal myocardial infarction, and non-fatal stroke.

284 ty, non-fatal myocardial infarction, and non-fatal stroke; HR 0.90, 95% CI 0.82-0.99; p=0.033), a 13%

285 A third of all disabling/fatal strokes occur in non-anticoagulated patients with

286 n-fatal myocardial infarction, fatal and non-fatal strokes, cardiovascular mortality, non-cardiovascu

287 anaplasmosis, a debilitating and potentially fatal tick-borne infection of cattle.

288 ronic wasting disease (CWD) is a universally fatal transmissible spongiform encephalopathy affecting

289 s, a globally distributed, debilitating, and fatal tumor disease of endangered marine turtles.

290 Mesothelioma is a fatal tumor of the pleura and is strongly associated wit

291 rP.IMPORTANCE Prion disorders are invariably fatal, untreatable diseases typically associated with lo

292 routine PPI use to prevent one disabling or fatal upper gastrointestinal bleed over 5 years fell fro

293 cannabis-related emergency room visits, and fatal vehicle crashes.

294 HRTV can cause rapidly fatal, widely disseminated infection with multisystem or

295 Mutations in ATP7B cause the potentially fatal Wilson disease, and changes in ATP7B expression ar

296 forme (GBM) is highly invasive and uniformly fatal, with median survival<20months after diagnosis eve

297 severely impaired T-cell development and is fatal without treatment.

298 Leptospirosis is potentially a fatal zoonosis acquired by contact of skin and mucosal s

299 r bacterium and tier 1 biothreat, causes the fatal zoonotic disease glanders.

300 rticles through axons.IMPORTANCE Rabies is a fatal zoonotic disease with a nearly 100% case fatality